Elanco Animal Health Conference Call Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date**: March 11, 2026 - **Key Speakers**: CFO Bob VanHimbergen, U.S. Business Head Bobby Modi Key Points Financial Performance - Elanco ended Q4 with strong performance, exceeding guidance on revenue, earnings, and cash flow, resulting in a reduction of debt levels [2][3] - Revenue from innovation basket reached **$892 million**, with expectations raised to **$1.15 billion** for 2026 [3] - Projected growth rates for 2026 include mid-single-digit top-line growth, high single-digit EBITDA growth, and low double-digit EPS growth [3] Product Innovations - **Credelio Quattro**: - Achieved a **40% market share** in the endectocide space, with significant growth potential as it is currently in only **1/3 of U.S. clinics** [4][5] - Approximately **35%** of Quattro's volume comes from new starts, indicating strong brand loyalty among new puppies [5] - **Zenrelia**: - Momentum increased in Q3 and Q4 of 2025, with **3,500 clinics** signed on, now present in over **50% of U.S. clinics** [8][9] - Ongoing collaboration with the FDA for label updates, which could enhance market share further [9][10] - **Befrena**: - Anticipated strong demand with **83%** of veterinarians indicating they would adopt the product [14] - Positioned to leverage existing clinics that already use Zenrelia for faster adoption [14][15] Market Dynamics - Elanco's corporate partnerships are gradually increasing, with **90%** of corporate partners seeing net sales growth in 2025, up from **13%** in 2024 [22] - The U.S. farm business grew **17%** in Q4, driven by strong performance from Experior, which has surpassed **$200 million** in annual revenue [29][25] - Favorable cattle market conditions are expected to continue, supported by high beef prices and favorable producer economics [30][32] Cost Management and Efficiency - Elanco Ascend program aims for **$250 million** EBIT improvement, with **$25 million** expected in 2026 from restructuring actions [37] - Anticipated **40 basis points** gross margin improvement in 2026, with further enhancements expected over the next several years [38] Strategic Focus - Continued emphasis on organic growth and debt reduction, with plans to reach leverage below **3 times** by 2027 [59] - Small tuck-under M&A opportunities will be pursued, focusing on enhancing R&D capabilities without derailing deleveraging efforts [60][61] Investor Insights - The pharmaceutical business is viewed as underappreciated, with efficient EBITDA margins comparable to the pet side [62] - The innovation pipeline is expected to drive growth across all business segments, with a focus on differentiated products in established markets [63] Conclusion - Elanco is positioned for growth through its innovative product pipeline, strong market presence, and strategic focus on efficiency and corporate partnerships. The company aims to leverage its strengths in both the pet and farm sectors to enhance shareholder value and drive long-term growth.

Elanco Animal Health Conference Call Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date**: February 26, 2026 - **Speakers**: Jeff Simmons (President and CEO), Bob VanHimbergen (Executive VP and CFO) Key Points Industry and Market Position - The animal health industry is experiencing positive trends, particularly in pet care and protein sectors, with Elanco positioned well within these markets [5][6] - Elanco's strategy focuses on growth, innovation, and cash generation, aiming to be a consistent and reliable performer [5][6] Financial Performance - Elanco reported strong Q4 results, exceeding expectations in adjusted EBITDA, revenue, and EPS [6] - Guidance for fiscal 2036 includes: - Mid-single-digit top-line growth - High single-digit EBITDA growth - Low double-digit EPS growth - Deleveraging to low threes by year-end [8][22] Innovation and Product Pipeline - Elanco's innovation pipeline is robust, with a focus on products like Zenrelia and Befrena, which are expected to drive future growth [10][12] - Zenrelia has shown strong market uptake, achieving 40% market share in Brazil and significant growth in the U.S. [13][15] - The company plans to increase investment in Zenrelia due to its positive performance and demand [14] Competitive Landscape - Elanco anticipates competitive responses from companies like Zoetis and Merck, but believes its product efficacy will maintain its market position [62][67] - The entry of new competitors, such as Merck's NUMELVI, is factored into Elanco's guidance, with expectations of continued market share growth [30][34] Pricing Strategy - Elanco has implemented a price increase of 2% in 2025, with expectations for further price uplift in 2026 due to new product launches [74][76] - The company emphasizes that market share gains are driven by product efficacy rather than pricing alone [74] Distribution Relationships - Elanco maintains strong relationships with major distributors, which are expected to provide a competitive advantage moving forward [78][80] - The company has a unique buy-sell model that allows for better value creation and demand generation [78] Long-term Outlook - Elanco expects to see EBITDA margins improve by 200 to 350 basis points by 2028, driven by volume leverage and a favorable product mix [88] - The Ascend initiative is expected to contribute significantly to operational efficiency and margin improvement [88] Additional Insights - The company is focused on maintaining a balanced approach to investment in innovation and operational efficiency, ensuring long-term growth [81][85] - Elanco's omnichannel approach is highlighted as a key strategy to enhance customer engagement and compliance in pet care [41] Conclusion Elanco Animal Health is positioned for growth in the animal health market, driven by a strong innovation pipeline, effective pricing strategies, and robust distribution relationships. The company is optimistic about its future performance, with a focus on maintaining product efficacy and market share amidst increasing competition.

Core Insights - Elanco Animal Health reported a full-year revenue of $4.715 billion, reflecting a 6% growth, with an organic constant-currency revenue growth of 7% projected for 2025 [1][8] - The company achieved an adjusted EBITDA of $901 million and an adjusted EPS of $0.94, an increase from $0.91 in 2024 [1] - Elanco's fourth-quarter revenue reached $1.14 billion, marking a 12% increase on a reported basis and a 9% organic constant-currency growth [3][4] Financial Performance - Full-year adjusted EBITDA was $901 million, with adjusted EPS at $0.94, up from $0.91 in 2024 [1] - Fourth-quarter adjusted EBITDA was $189 million, a 7% year-over-year increase, while adjusted EPS was $0.13, down 7% due to a higher anticipated tax rate [2] - The full-year adjusted gross margin was 54.9%, remaining flat compared to 2024, as inflation and higher manufacturing costs offset price and volume benefits [1] Growth and Innovation - Elanco's innovation revenue for 2025 was $892 million, with a raised outlook for 2026 to $1.15 billion, indicating at least $250 million growth year-over-year [7][9] - Key products driving growth include Credelio Quattro, Zenrelia, and the soon-to-launch Befrena, with Credelio Quattro being highlighted as the fastest blockbuster in the company's history [9] - The company reported strong performance in U.S. Farm Animal and U.S. Pet Health segments, with growth rates of 17% and 10% respectively in the fourth quarter [4] Strategic Initiatives - Elanco's net leverage improved to 3.6x by year-end 2025, with a target of 3.1–3.3x by the end of 2026, and net debt reported at approximately $3.2 billion [6][14] - The company announced an agreement to acquire AHV International, expected to contribute modestly in 2026 and more significantly in 2027 [6][15] - Management is focused on cash generation and has initiated a company-wide productivity initiative, Elanco Ascend, aimed at achieving $25 million in savings in 2026 [16] Market Dynamics - Elanco expects accelerating price contributions in 2026, with 2025 price growth at about 2% [10] - The company noted strong relationships with major distributors, with 90% of corporate accounts growing in 2025 compared to 13% in 2024 [11][13] - There were no significant changes in distributor stocking trends, with strong dispensing patterns observed [12] 2026 Guidance - For 2026, Elanco guided organic revenue growth of 4–6%, with projected revenue between $4.95 billion and $5.02 billion, adjusted EBITDA of $955–$985 million, and adjusted EPS of $1.00–$1.06 [8][18] - The first-quarter guidance includes revenue of $1.28 billion to $1.305 billion and adjusted EBITDA of $290 million to $310 million [15]

Financial Data and Key Metrics Changes - Elanco reported $1.14 billion in revenue for Q4 2025, a 12% increase year-over-year, with 9% organic constant currency growth driven primarily by volume increases [24][25] - Full-year revenue reached $4.715 billion, representing a 6% growth compared to 2024, with adjusted EBITDA of $901 million and adjusted EPS of $0.94, up from $0.91 in 2024 [27][28] - The net leverage ratio improved to 3.6x at year-end, with expectations to reduce it to 3.1x-3.3x in 2026 [6][30] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue grew 10% in Q4, driven by key innovation products like Credelio Quattro and Zenrelia, while international pet health grew 8% [24][25] - U.S. Farm Animal business achieved a 17% growth in Q4, with strong contributions from products like Experior and Pradalex, while international farm animal grew 4% [25][9] - Innovation revenue for 2025 was $892 million, with expectations to reach $1.15 billion in 2026 [5][10] Market Data and Key Metrics Changes - The U.S. broad-spectrum parasiticide market is growing at 30% year-over-year, with Credelio Quattro gaining significant market share [12][11] - Zenrelia achieved over 30% market share in Japan and 40% in Brazil, indicating strong international performance [15][14] - The overall animal health market is projected to add $20 billion in value over the next decade, with Elanco positioned to capitalize on this growth [36][39] Company Strategy and Development Direction - Elanco is focused on growth, innovation, and cash management, with a commitment to introducing new products and enhancing its portfolio [5][20] - The acquisition of AHV International is aimed at expanding Elanco's leadership in the dairy industry, particularly in North America and Europe [21][22] - The company is implementing a productivity initiative, Elanco Ascend, to drive efficiencies and margin enhancements starting in 2026 [34][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elanco's trajectory, highlighting strong momentum and a commitment to transforming animal care [35][40] - The company anticipates sustainable revenue growth driven by innovation and strategic pricing, despite competitive pressures [33][76] - Management acknowledged the impact of inflation and competitive responses on their guidance, emphasizing a balanced approach to growth [76][75] Other Important Information - Adjusted gross margin increased to 54.9% for the full year, flat compared to 2024, with price and volume benefits offset by inflationary pressures [27][26] - The effective tax rate for 2025 was 21.8%, a year-over-year increase due to the recognition of non-recurring tax credits in 2024 [28][27] Q&A Session Summary Question: Insights on Zenrelia's international share gains - Management noted that Zenrelia's efficacy is driving rapid share gains in international markets, with significant momentum in Japan and Brazil [44][45] Question: Impact of Covetrus and MWI merger on Elanco - Management emphasized strong relationships with distributors and the value they add, indicating confidence in navigating the evolving distribution landscape [50][51] Question: Clarification on pricing strategy for 2026 - Management expects price growth to accelerate in 2026, reflecting the enhanced value of their innovation and comprehensive portfolio [57][58] Question: Stocking dynamics and competitive positioning in parasiticides - Management reported strong dispensing demand with no significant stocking issues, positioning Elanco favorably in the parasiticides market [66][67] Question: Timeline for Zenrelia label update in the U.S. - Management confirmed constructive dialogue with the FDA regarding the label update, with expectations for alignment with international standards [69][70]

Core Insights - Elanco Animal Health reported significant financial results for Q4 and full year 2025, with a focus on growth, innovation, and cash generation, and provided guidance for 2026 [1][2][3] Financial Performance - Q4 2025 revenue reached $1,144 million, a 12% increase year-over-year, with 9% organic constant currency growth [2][3] - Full year 2025 revenue was $4,715 million, up 6% on a reported basis and 7% in organic constant currency [1][2] - Adjusted EBITDA for Q4 2025 was $189 million, with a margin of 16.7%, while full year adjusted EBITDA was $901 million, representing a margin of 19.2% [1][2] - The company reported a net loss of $276 million for Q4 2025 and a net loss of $232 million for the full year [2][3] Business Segments - Pet Health segment revenue for Q4 2025 was $489 million, an 11% increase, driven by new products like Credelio Quattro and Zenrelia [2][3] - Farm Animal segment revenue was $640 million in Q4 2025, a 12% increase, supported by volume growth in cattle and poultry [2][3] Innovation and Growth Strategy - Elanco exceeded its innovation revenue target for 2025, achieving $892 million, and raised the target for 2026 to $1.15 billion [1][2] - The company plans to continue its focus on innovation, with expectations of five to six blockbuster-potential approvals over the next six years [1][2] Financial Guidance - For full year 2026, Elanco expects revenue between $4,950 million and $5,020 million, representing 4% to 6% organic constant currency growth [1][3] - Adjusted EBITDA guidance for 2026 is set at $955 million to $985 million, with adjusted EPS expected to be between $1.00 and $1.06 [1][3] Restructuring and Cost Management - The company recorded $155 million in restructuring costs in Q4 2025, with expected savings of approximately $25 million in 2026 and $60 million in 2027 [1][2] - Elanco's net leverage ratio improved to 3.6x adjusted EBITDA by the end of 2025, with a target of reducing it to below 3x by 2027 [1][3]

Core Viewpoint - Elanco Animal Health Incorporated (NYSE:ELAN) is gaining positive attention from hedge funds and analysts, with multiple price target increases reflecting strong operational performance and growth potential in the animal health sector [1][2][3]. Group 1: Analyst Ratings and Price Targets - BofA raised the price target on Elanco to $28 from $25 while maintaining a Buy rating, indicating confidence in the company's upcoming fiscal Q4 earnings [1]. - UBS increased its price target to $30 from $27 and reaffirmed a Buy rating, showcasing a bullish outlook on Elanco's stock [2]. - Piper Sandler upgraded Elanco from Neutral to Overweight and raised the price target to $30 from $24, further indicating strong market sentiment [2]. Group 2: Market Developments and Corporate Strategy - Following the VMX conference, analysts noted that Elanco is making significant progress with corporate groups, suggesting that this channel could become a new growth driver for the company [3]. - There is minimal resistance anticipated regarding price increases on Elanco's core products, indicating confidence in the company's pricing strategy [3]. Group 3: Company Overview - Elanco is an animal health company that provides products and services aimed at preventing and treating diseases in both pets and farm animals, with a diverse portfolio that includes various species such as cats, dogs, cattle, swine, poultry, and sheep [4].

Group 1: Fund Performance - Baron Health Care Fund rose 13.10% in Q4 2025, outperforming the Russell 3000 Health Care Index which gained 11.92% and the Russell 3000 Index which gained 2.40% [1] - For the full year, the Fund returned 10.28%, compared to 14.56% and 17.15% gains for the respective indexes [1] - Strong stock selection in biotechnology contributed to the Fund's relative gains in the quarter [1] Group 2: Investment Focus - The Fund seeks to invest in businesses with secular growth opportunities, sustainable competitive edges, and strong management [1] - The healthcare sector is viewed as a strong area in the U.S. economy, offering attractive investment opportunities with positive momentum heading into 2026 [1] Group 3: Elanco Animal Health Incorporated - Elanco Animal Health has a market capitalization of $12.079 billion and closed at $24.31 per share on February 5, 2026 [2] - The stock gained 3.58% over the past month and 111.02% over the last 52 weeks [2] - Elanco operates in an attractive industry with growth drivers such as increased pet ownership and higher spending on pets [3] Group 4: Innovation and Growth Potential - Elanco's management expects innovation revenue to reach $840 million to $880 million in 2025, increasing to $1.1 billion in 2026 [3] - Key innovation products include Credelio Quattro, Zenrelia, Befrena, Bovaer, and Experior, which are expected to drive growth and gross margin expansion [3] - The innovation pipeline includes five to six additional products expected to be approved between 2026-2031, with potential peak sales of $2 billion [3] Group 5: Financial Targets - Management targets 200-350 basis points of EBITDA margin expansion from 2025-2028 [3] - The company aims for $1 billion of cumulative free cash flow from 2026-2028 to pay down debt and reduce net debt to EBITDA from 3.7-3.8 times at the end of 2025 to 2.0-2.5 times by the end of 2028 [3]

Financial Performance and Outlook - Elanco expects organic constant currency revenue growth starting in 2025[10] - The company anticipates adjusted EBITDA growth starting in 2026[10] - Elanco projects over $1 billion in total free cash flow from 2026 to 2028[10] - The company aims to reduce net leverage to below 3x in 2027 and further towards 20x-25x[10] - Elanco expects innovation to deliver $11 billion in revenue in 2026, compared to $840-$880 million in 2025[90] Innovation and Pipeline - Elanco's innovation engine is expected to generate $840-$880 million in revenue in 2025[34] - The "Big 6" products are projected to drive $11 billion in innovation revenue in 2026[39] - The company anticipates 5-6 potential blockbuster approvals between 2026 and 2031, with peak sales exceeding $2 billion[10, 61, 90] - Elanco's "Next Wave" innovation portfolio includes over 15 projects across 8 innovation spaces[58, 59] Market and Industry Trends - The animal health industry is projected to grow from $42 billion to $60 billion[11] - The pet health industry is a $17 billion market experiencing mid-single-digit to high-single-digit growth[16] - The farm animal health industry is a $25 billion market with low-single-digit to mid-single-digit growth[17] Elanco Ascend and Cost Savings - Elanco Ascend is expected to generate approximately $200-$250 million in adjusted EBITDA savings by 2030, net of inflation and reinvestment[71, 90] - The company anticipates approximately $25 million in savings in 2026, $60 million in 2027, and $130 million in cash cost[90]

Core Viewpoint - Elanco Animal Health is entering a new phase focused on sustainable growth, margin expansion, and a stronger balance sheet, as outlined during its first Investor Day in five years [1] Financial Outlook - Elanco projects mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth starting in 2026 [2] - The company anticipates free cash flow of at least $1 billion from 2026 to 2028, with net leverage expected to fall below 3x in 2027, targeting a long-term range of 2.0x to 2.5x [2] R&D Investments - Elanco plans to expand R&D operations in Indianapolis and increase its U.S.-based manufacturing footprint, including investments in its Kansas monoclonal antibody facility [3] - The company expects approximately $1.1 billion in revenue from its innovation portfolio in 2026, an increase from prior expectations for 2025 [4] - Elanco has expanded its focus to eight innovation areas and added two new internal development platforms in monoclonal antibodies and immunotherapy [4] - More than 10 major pipeline programs are in place, with approvals expected for five to six differentiated assets between 2026 and 2031 [5] Cost Initiatives - Elanco detailed its Ascend productivity initiative, expecting $25 million in savings in 2026 and $60 million in 2027, affecting 600 roles through reductions or shifts [6] - A related charge of approximately $175 million is anticipated, with the Ascend program expected to deliver $200 to $250 million in adjusted EBITDA savings by 2030, achieving about 30% of this in 2026 [6] Analyst Insights - Analysts noted initial details on over 15 projects in key areas, including five to six blockbusters, positioning Elanco for three waves of innovation over the next decade [9] - If Elanco successfully executes its pipeline, it is expected to deliver upside to its long-term financial targets [9] - Elanco shares were trading at 21 times the 2026 EPS estimate, with an Outperform rating maintained by analysts [10]

Core Viewpoint - Elanco Animal Health is entering a new phase focused on sustainable growth, margin expansion, and a stronger balance sheet, as outlined during its first Investor Day in five years [1] Financial Outlook - Elanco projects mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth starting in 2026 [2] - The company anticipates free cash flow of at least $1 billion from 2026 to 2028, with net leverage expected to fall below 3x in 2027, targeting a long-term range of 2.0x to 2.5x [2] R&D Investments - Elanco plans to expand R&D operations in Indianapolis and increase its U.S.-based manufacturing footprint, including investments in its Kansas monoclonal antibody facility [3] - The company is progressing towards final USDA approval for Befrena, a potential blockbuster dermatitis treatment for dogs, with a launch expected in the first half of 2026 [4] - Elanco forecasts approximately $1.1 billion in revenue from its innovation portfolio in 2026, an increase from prior expectations for 2025 [4] - The company has expanded its focus to eight innovation areas and added two new internal development platforms in monoclonal antibodies and immunotherapy [4] - More than 10 major pipeline programs are expected to carry blockbuster potential, with approvals anticipated for five to six differentiated assets between 2026 and 2031 [5] Cost Initiatives - Elanco detailed its Ascend productivity initiative, expecting $25 million in savings in 2026 and $60 million in 2027, affecting 600 roles through reductions or shifts [6] - A related charge of approximately $175 million is anticipated, with the Ascend program expected to deliver $200 to $250 million in adjusted EBITDA savings by 2030, with about 30% achieved in 2026 [6] - The initiative positions Elanco for durable, profitable growth with continued margin expansion and strong cash generation into the latter half of the decade [7] Analyst Insights - Analysts noted initial details on over 15 projects in key areas, including five to six blockbusters, positioning Elanco for three waves of innovation over the next decade [9] - If Elanco successfully executes its pipeline, it is expected to deliver upside to its long-term financial targets [9] - Elanco shares were trading at 21 times the 2026 EPS estimate, with an Outperform rating maintained by analysts [10]